genedrive PLC (AIM:GDR) shares fell 10% after it was revealed CEO James Cheek had left the company by mutual agreement.
Dr Gino Miele, previously chief scientific officer, has been appointed as the new CEO.
Miele, who joined Genedrive in 2011, has contributed to the development of the company's pharmacogenomic testing products.
He has overseen regulatory approvals in the UK, Europe, and the Middle East, and secured NICE approvals for the Genedrive MT-RNR1 and CYP2C19 ID Kits.
Miele also played a pivotal role in obtaining the FDA breakthrough device designation and is focused on expanding revenue opportunities in the UK and internationally.
In early trading the stock was down 0.3p at 2.8p.